Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment

Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment

Pancreatic cancer is one of the most common causes of death in Taiwan. Previous studies have shown that more than 90% of pancreatic cancer cells presented epidermal growth factor receptor (EGFR) cell marker, and this marker is thought to be important as it is related to activation of cancer cell pro...

Full description

Bibliographic Details
Main Authors: Hung-Jun Lin, Tien-Li Liang, Yao-Yuan Chang, Der-Zen Liu, Jia-Yu Fan, Steve R. Roffler, Shyr-Yi Lin
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceutics
Subjects:
pancreatic cancer
liposomal drug
targeted liposome
bispecific targeting antibody
Online Access:https://www.mdpi.com/1999-4923/14/6/1202

Internet

https://www.mdpi.com/1999-4923/14/6/1202

Similar Items